Trevi Therapeutics (NASDAQ:TRVI) just reported results for the fourth quarter of 2023.
- Trevi Therapeutics reported earnings per share of -8 cents. This was above the analyst estimate for EPS of -9 cents.
- The company did not report any revenue for the quarter.